Drug discovery has always been a complex and multi-faceted process that requires the integration of various disciplines such as biology, chemistry, and computer science. Today Artificial Intelligence is revolutionizing the way we discover and develop drugs, opening up new possibilities and unlocking insights that were once out of reach. Empowering us to see the invisible and make connections that were previously unknowable.
Join CEO Robert T. Foster and Senior VP Patrick R. Mayo of Hepion Pharmaceuticals Inc. and CEO, President, and Director Panna Sharma of Lantern Pharma, Inc. as they discuss the forefront of how AI is impacting drug discovery.
This ACS Webinar is co-produced with The Joseph Priestley Society at the Science History Institute and is moderated by Founder, President, and CEO Maria L. Maccecchini Annovis Bio and Partner Bill Tuszynski of The Unami Group, LLC.
The Joseph Priestley Society at the Science History Institute invites monthly speakers who are leaders from a wide variety of chemical and life science companies to promote a deeper understanding of science, technology, and industry.
Very good webinar on the use of AI in drug discovery and very informative examples and discussion.
Robert T. Foster
Chief Executive Officer, Hepion Pharmaceuticals Inc.
Patrick R. Mayo
Senior Vice President, Clinical Pharmacology, Hepion Pharmaceuticals Inc.
Chief Executive Officer, President, and Director, Lantern Pharma, Inc.
Maria L. Maccecchini
Founder, President, and CEO,
Partner, The Unami Group, LLC.